AbbVie 8K Results of Operations and Financial Condition | ABBV 29 Jul 20

Exhibit 99.1

AbbVie Inc.

Key Product Revenues

Quarterly Trend Analysis

(Unaudited, in millions)

	1Q19						2Q19						3Q19						4Q19						FY19						1Q20
	U.S.		Int’l.		Total		U.S.		Int’l.		Total		U.S.		Int’l.		Total		U.S.		Int’l.		Total		U.S.		Int’l.		Total		U.S.		Int’l.		Total
NET REVENUES	$	5,270	$	2,558	$	7,828	$	5,964	$	2,291	$	8,255	$	6,244	$	2,235	$	8,479	$	6,429	$	2,275	$	8,704	$	23,907	$	9,359	$	33,266	$	6,158	$	2,461	$	8,619

Immunology	3,215		1,231		4,446		3,835		1,083		4,918		3,977		1,064		5,041		4,195		971		5,166		15,222		4,349		19,571		4,004		1,085		5,089
Humira	3,215		1,231		4,446		3,793		1,077		4,870		3,887		1,049		4,936		3,969		948		4,917		14,864		4,305		19,169		3,656		1,047		4,703
Skyrizi	—		—		—		42		6		48		76		15		91		193		23		216		311		44		355		266		34		300
Rinvoq	—		—		—		—		—		—		14		—		14		33		—		33		47		—		47		82		4		86

Hematologic Oncology	934		239		1,173		1,003		265		1,268		1,184		294		1,478		1,230		317		1,547		4,351		1,115		5,466		1,167		382		1,549
Imbruvica^a	829		193		1,022		886		213		1,099		1,042		215		1,257		1,073		223		1,296		3,830		844		4,674		966		266		1,232
Venclexta	105		46		151		117		52		169		142		79		221		157		94		251		521		271		792		201		116		317

Aesthetics	—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—
Botox Cosmetic*	—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—
Juvederm Collection*	—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—
Other Aesthetics*	—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—

Neuroscience	22		89		111		24		91		115		26		91		117		25		93		118		97		364		461		25		99		124
Botox Therapeutic*	—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—
Vraylar*	—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—
Duodopa	22		89		111		24		91		115		26		91		117		25		93		118		97		364		461		25		99		124
Ubrelvy*	—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—
Other Neuroscience*	—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—

Eye Care	—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—
Lumigan/Ganfort*	—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—
Alphagan/Combigan*	—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—
Restasis*	—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—
Other Eye Care*	—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—

Women's Health	13		—		13		18		1		19		27		—		27		33		1		34		91		2		93		30		1		31
Lo Loestrin*	—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—
Orilissa	13		—		13		18		1		19		27		—		27		33		1		34		91		2		93		30		1		31
Other Women's Health*	—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—

Other Key Products	1,003		425		1,428		1,024		425		1,449		1,017		370		1,387		976		367		1,343		4,020		1,587		5,607		910		363		1,273
Mavyret	403		387		790		396		384		780		368		327		695		306		322		628		1,473		1,420		2,893		234		325		559
Creon	227		—		227		257		—		257		265		—		265		292		—		292		1,041		—		1,041		276		—		276
Lupron	191		38		229		168		41		209		187		43		230		174		45		219		720		167		887		195		38		233
Linzess/Constella*	—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		—
Synthroid	182		—		182		203		—		203		197		—		197		204		—		204		786		—		786		205		—		205

^aReflects profit sharing for Imbruvica international revenues.

* Represents product(s) acquired as part of the Allergan acquisition.

AbbVie Inc.

Key Product Revenues

Quarterly Comparable Historical Trend Analysis^{a, b}

(Unaudited, in millions)

	1Q19						2Q19						3Q19						4Q19						FY19						1Q20
	U.S.		Int’l.		Total		U.S.		Int’l.		Total		U.S.		Int’l.		Total		U.S.		Int’l.		Total		U.S.		Int’l.		Total		U.S.		Int’l.		Total
NET REVENUES	$	8,031	$	3,359	$	11,390	$	9,130	$	3,137	$	12,267	$	9,334	$	3,069	$	12,403	$	9,751	$	3,192	$	12,943	$	36,246	$	12,757	$	49,003	$	9,018	$	3,151	$	12,169

Immunology	3,215		1,231		4,446		3,835		1,083		4,918		3,977		1,064		5,041		4,195		971		5,166		15,222		4,349		19,571		4,004		1,085		5,089
Humira	3,215		1,231		4,446		3,793		1,077		4,870		3,887		1,049		4,936		3,969		948		4,917		14,864		4,305		19,169		3,656		1,047		4,703
Skyrizi	—		—		—		42		6		48		76		15		91		193		23		216		311		44		355		266		34		300
Rinvoq	—		—		—		—		—		—		14		—		14		33		—		33		47		—		47		82		4		86

Hematologic Oncology	934		239		1,173		1,003		265		1,268		1,184		294		1,478		1,230		317		1,547		4,351		1,115		5,466		1,167		382		1,549
Imbruvica^c	829		193		1,022		886		213		1,099		1,042		215		1,257		1,073		223		1,296		3,830		844		4,674		966		266		1,232
Venclexta	105		46		151		117		52		169		142		79		221		157		94		251		521		271		792		201		116		317

Aesthetics	648		353		1,001		737		357		1,094		646		358		1,004		742		413		1,155		2,773		1,481		4,254		587		250		837
Botox Cosmetic*	230		147		377		252		176		428		238		166		404		272		183		455		992		672		1,664		213		114		327
Juvederm Collection*	129		158		287		157		173		330		135		144		279		167		181		348		588		656		1,244		108		113		221
Other Aesthetics*	289		48		337		328		8		336		273		48		321		303		49		352		1,193		153		1,346		266		23		289

Neuroscience	780		185		965		903		192		1,095		923		189		1,112		1,005		198		1,203		3,611		764		4,375		919		192		1,111
Botox Therapeutic*	403		94		497		454		99		553		439		93		532		469		103		572		1,765		389		2,154		402		89		491
Vraylar*	148		—		148		201		—		201		241		—		241		291		—		291		881		—		881		285		—		285
Duodopa	22		89		111		24		91		115		26		91		117		25		93		118		97		364		461		25		99		124
Ubrelvy*	—		—		—		—		—		—		—		—		—		—		—		—		—		—		—		13		—		13
Other Neuroscience*	207		2		209		224		2		226		217		5		222		220		2		222		868		11		879		194		4		198

Eye Care	505		292		797		594		327		921		577		313		890		610		319		929		2,286		1,251		3,537		607		283		890
Lumigan/Ganfort*	70		85		155		69		91		160		69		89		158		79		96		175		287		361		648		81		81		162
Alphagan/Combigan*	91		38		129		98		41		139		94		40		134		95		43		138		378		162		540		92		37		129
Restasis*	248		10		258		315		12		327		300		10		310		331		18		349		1,194		50		1,244		314		11		325
Other Eye Care*	96		159		255		112		183		295		114		174		288		105		162		267		427		678		1,105		120		154		274

Women's Health	230		8		238		262		10		272		280		11		291		285		13		298		1,057		42		1,099		219		9		228
Lo Loestrin*	129		3		132		150		3		153		167		3		170		161		5		166		607		14		621		114		3		117
Orilissa	13		—		13		18		1		19		27		—		27		33		1		34		91		2		93		30		1		31
Other Women's Health*	88		5		93		94		6		100		86		8		94		91		7		98		359		26		385		75		5		80

Other Key Products	1,181		430		1,611		1,231		430		1,661		1,237		377		1,614		1,216		374		1,590		4,865		1,611		6,476		1,103		370		1,473
Mavyret	403		387		790		396		384		780		368		327		695		306		322		628		1,473		1,420		2,893		234		325		559
Creon	227		—		227		257		—		257		265		—		265		292		—		292		1,041		—		1,041		276		—		276
Lupron	191		38		229		168		41		209		187		43		230		174		45		219		720		167		887		195		38		233
Linzess/Constella*	178		5		183		207		5		212		220		7		227		240		7		247		845		24		869		193		7		200
Synthroid	182		—		182		203		—		203		197		—		197		204		—		204		786		—		786		205		—		205

^aComparable historical net revenues include total revenues for all reported periods for both AbbVie and Allergan products as if the acquisition had closed on January 1, 2019.

^bAll historically reported Allergan revenues have been recast to conform to AbbVie's revenue recognition accounting policies and reporting conventions for certain rebates and discounts. Historically reported Allergan revenues also exclude Zenpep and Viokace product revenues, which were both divested as part of the acquisition, as well as specified items.

^cReflects profit sharing for Imbruvica international revenues.

* Represents product(s) acquired as part of the Allergan acquisition.

AbbVie (ABBV) 8-KResults of Operations and Financial Condition